tbuckley/cabot-search huggingface dataset:
Physicians and medical education
Authors: G. T. Bryan
Journal: JAMA (1991)

Certain occasions prompt evaluation of and reflection on our current state of affairs and our future direction. Such is the case with the centennial of The University of Texas Medical School at Galveston. Inasmuch as a medical school provides the foundation for future physicians to practice medicine with compassion and to actively seek solutions to medical dilemmas, interpersonal skills and critical thinking are essential to the future of medicine. We must face the problems encountered in the process of educating physicians and implement changes that assure that these elements of compassion and critical analysis are passed on to our future colleagues. Physicians who are engaged in the practice of medicine on a full-time basis (hereafter referred to as practicing physicians) can help us impart these elements to our students. In addition, they can help identify other essential components of medical practice that should become part of medical education. A central
Selected Articles from This Issue
Journal: Clinical Cancer Research (2021)

Mutations in ALK are common in neuroblastoma, rendering ALK an attractive therapeutic target. Foster and colleagues conducted a phase I/II clinical trial of the ALK inhibitor crizotinib in children with neuroblastoma. Crizotinib was well tolerated in this population. The objective response rate was 15%, with two patients showing a partial response and one patient showing a complete response. Interestingly, all three responders' tumors harbored the same somatic ALK R1275Q mutation. Two additional patients with this mutation had prolonged stable disease, although patients with other hotspot mutations or amplification of ALK did not respond to crizotinib. Further study will elucidate whether third generation ALK inhibitors will prove more effective against a broader spectrum of ALK mutations in neuroblastoma.Although immunotherap. has emerged as an important treatment strategy for many cancers, many patients either do not respond or progress on treatment, indicating that additional strategies for immunotherapy are needed. Curigliano and colleagues performed a phase I clinical trial of sabatolimab, an anti-TIM-3 antibody, with or without spartalizumab, an anti-PD-1 antibody, in patients with solid tumors. A maximum tolerated dose was not reached. Although no responses were observed for sabatolimab alone, combination treatment led to partial responses in 5 patients and prolonged stable responses in 9 patients. Further trials are underway to further determine the therapeutic relevance of TIM-3 in solid and hematologic malignancies.Pepinemab is a first-in-class monoclonal antibody that blocks the activity of SEMA4D, a potent regulator of immune cell migration and of the maturation and activity of myeloid suppressor cells. Shafique and colleagues performed a phase Ib/II clinical trial assessing the combination of pepinemab and avelumab, a PD-L1 inhibitor, in patients with lung cancer (the CLASSICAL-Lung trial). This combination was well tolerated and demonstrated antitumor activity in some patients who failed prior therapy with single-agent checkpoint inhibitors as well as in immunotherapy naïve patients with challenging PD-L1 negative or low tumors. These results show promise and warrant additional trials of pepinemab in combination with checkpoint inhibitors in other cancer indications.PSMA-targeted PET imaging has been considered a promising strategy for detecting prostate cancer that evades standard imaging techniques. Morris and colleagues performed a prospective clinical trial (CONDOR) designed to definitively establish the diagnostic performance of 18F-DCFPyL-PET/CT in patients with biochemical recurrence of prostate cancer and uninformative standard imaging. The trial demonstrated that the radiotracer correctly localized disease in approximately 85% of men, leading to a changed disease management plan in 64% of cases. This study adds greatly to the evidence base in support of the value of PSMA-PET/CT in the management of prostate cancer.
Corrections
Journal: Endoscopy (2010)

Correction to: Endoscopic submucosal dissection assisted by novel “clip fishing method” (with video)Endoscopy 2010; 42(S 02): E277-E278DOI: 10.1055/s-0029-1243986 Correction to: Diagnostic cholangioscopy with SpyGlass probe through an endoscopic retrograde cholangiopancreatography cannulaEndoscopy 2010; 42(S 02): E288-E289DOI: 10.1055/s-0030-1255707 Correction to: Intestinal lymphangiectasia presenting with duodeno-jejunal polyposis: enteroscopic findingsEndoscopy 2010; 42(S 02): E281-E282DOI: 10.1055/s-0029-1244225 Correction to: Primary eosinophilic colitis as an unusual cause of chronic diarrheaEndoscopy 2010; 42(S 02): E279-E280DOI: 10.1055/s-0029-1244167 Correction to: Endoscopic diagnosis of a gastric small cell carcinoma with liver metastasisEndoscopy 2010; 42(S 02): E283-E284DOI: 10.1055/s-0030-1255533 Correction to: Desquamative esophagitis due to pemphigus vulgarisEndoscopy 2010; 42(S 02): E285-E285DOI: 10.1055/s-0030-1255569 Correction to: Ulcer in Barrett’s esophagus probably related to severe kyphosisEndoscopy 2010; 42(S 02): E286-E287DOI: 10.1055/s-0030-1255596
Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).
Authors: P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, V. Andre, K. Hurt, M. M. F. Lahn, M. Stöckle, C. Reuter, B. Heinrich
Journal: Journal of Clinical Oncology (2011)

4592 Background: Survivin is a member of the inhibitor of apoptosis proteins (IAP). Its expression in prostate cancer is associated with resistance to taxanes and poor outcome. LY2181308 reduces survivin expression and consequently is expected to improve activity of taxanes, such as docetaxel. A randomized phase II study was conducted to assess the activity of the combination. Methods: 150 patients were randomized to standard docetaxel/prednisone every 21 days (Arm A) or LY2181308 as a 3-hour IV loading dose on three consecutive days followed by weekly 3-hr IV maintenance doses (Arm B). The experimental arm also included a window of monotherapy of LY2181308 equivalent to a 21-day cycle of docetaxel prior to starting combined treatment. There were two planned interim analyses, after 20 and 60 patients respectively, to assess safety and futility. The primary endpoint is progression-free-survival (PFS). Results: The addition of LY2181308 to standard first-line treatment in CRPC showed no significant increase in toxicity compared to docetaxel treatment alone. Neutropenia grade 3/4 was observed in 11/40 (23%) in Arm B versus 2/20 (10%) in Arm A. There was no febrile neutropenia, grade 3/4 anemia or thrombocytopenia in either arm. The only important difference for Arm B was grade 1/2 thrombocytopenia (17/40; 43%) and anemia (13/40; 33%), which was not present in Arm A. Toxicity of LY2181308 in the window period was mild (nonhematologic grade 1/2 toxicities) as previously described. These toxicities were manageable, and did not increase with addition of docetaxel. The PK profile for both docetaxel and LY2181308 was as previously described. Conclusions: The manageable toxicity profile of the combination of LY2181308 and docetaxel justified continuation of the phase II study. Enrollment of 150 patients has been completed and PFS data are expected in 2011.
The shadow of Hiroshima: two diaries
Authors: M. T. Southgate
Journal: JAMA (1984)

Although no longer recent, two little books, slim enough to be slipped into a pocket, deserve to be read—or reread, as the case may be—by all physicians. Both are diaries, both are written by physicians, and both concern Hiroshima in 1945. Both are timeless. The first,<i>Hiroshima Diary</i>,<sup>1</sup>covers two months in the life of Michihiko Hachiya, MD, from Aug 6, 1945, to Sept 30, 1945. The second,<i>Encounter With Disaster</i>,<sup>2</sup>picks up a little before the first ends and covers just under three months in the life of Averill Liebow, MD, from Sept 18, 1945, to Dec 10, 1945. At the time the accounts were written, Dr Hachiya was a civilian physician in charge of the Hiroshima Communications Hospital, a 125-bed hospital with a large outpatient population, which served workers in the postal, telegraph, and telephone services. Dr Liebow was a lieutenant colonel in the US Army
Abstracts
Journal: Thorax (1952)

Medicine, and Abstracts of World Surgery, Obstetrics and Gynaecology, published by the British Medical Association.In this Journal some of the more important articles on subjects of interest to chest physicians and surgeons are selected for abstract, and these are classified.No one section is necessarily represented in any one issue. ExperimentalTissue Changes in the Lungs after Bronchography with "Ioduran B." VISCHER, W. (1951).Schweiz.med.Wschr., 81.54.Pathological changes in the lungs following broncho- graphy with oily suspensions of iodine have long been recognized and " lipiodol " itself was held to be respon- sible.In 1948 Fischer.and Muilly introduced a watery suspension containing 50% iodine and made viscous by the addition of cellulose-ethyl-glycolic acid.In animals this medium was fully absorbed after 24 hours and was radiologically invisible after 3 to 4 hours, but histological changes were present which could not be adequately explained.To investigate this the author injected " ioduran B " into the bronchial tree of animals.As the medium was not visible after a short time it was thought that the cellulose-ethyl-glycolic acid might be responsible.This was therefore injected separately into rats and guinea-pigs.It was found that the changes were identical to those produced by ioduran B. When the animals were killed immediately following the injection the medium was mostly in the bronchi, and a few erythrocytes were present in the alveoli.Lung-tissue changes did not occur until the end of one hour, when there was a blood-stained exudate with lymphocytes and leucocytes around the medium.After 24 hours the on August 15,
Recurrent conjugal neuralgia caused by Herpesvirus hominis type 2
Authors: D. R. Hinthorn
Journal: JAMA (1976)

Leg neuralgia is usually caused by nerve root irritation, and is seldom considered of viral origin. Two married couples had recurrent leg pain in a dermatome distribution. In each episode, after one to three days of neuralgia, herpetic vesicles appear on or near the genitalia. Herpesvirus hominis (HVH) was isolated from vesicles or cervix in three patients and was serologically identified as herpesvirus hominis type 2. Prolonged follow-up has not shown progression of the syndrome or any permanent neurologic damage. Treatment with topical neutral red and photoinactivation has not only reduced local lesion healing time and frequency of attacks, but it has also given prompt relief of neuralgia. (<i>JAMA</i>236:587-588, 1976)
Recueil des Travaux du Comité Consultatif d'Hygiène Publique de France et des Actes Officiels de l'Administration Sanitaire.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oncology as a Teaching Specialty
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MIGRAINE AND EPILEPSY.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical War Crimes
Authors: A. P. Tait
Journal: BMJ (1958)

I have no objection to the public receiving cancer educa- tion as advocated by Professor Aird, provided it is based on truth, but can this be done at this time ?May I draw the attention of your readers who are interested in this subject to two particularly informative and thoughtful articles which have probably been neglected because they do not subscribe to popular orthodox
Rheumatology
Authors: G. E. Ehrlich
Journal: JAMA (1980)

When a syndrome or a disease is newly described, a question arises as to whether the disease is truly new or only newly recognized. The 1970s saw the emergence of such a disease, Lyme arthritis. No evidence suggests that it existed before 1965; it was discovered in 1975, investigated and described during the next five years, and, by the end of 1979, just about fully understood. Although the causative agent has not been isolated, the elucidation of Lyme arthritis represents one of the most fascinating pieces of detective work, by rheumatologists at Yale University.<sup>1-5</sup> A geographic clustering of children with relatively evanescent arthritis, originally thought to be juvenile rheumatoid arthritis by their physicians, drew attention to the small community of Lyme, Conn.<sup>4</sup>The attacks were recurrent and included monoarthritis, oligoarthritis, and even migratory arthritis. They seemed to leave no residua. Gradually, there emerged a history of a prior
Structure of Peptides Associated with Class I and Class II MHC Molecules
Authors: V. H. Engelhard
Journal: Annual Review of Immunology (1994)

Class I and class II molecules encoded by genes within the major histocompatibility complex play a central role in regulation of immune responses through their ability to bind and display small peptides derived from foreign antigens. Within the last few years, considerable progress has been made in understanding the structures of class I and class II MHC molecules, as well as the features of the peptides that are their principal ligands. This review summarizes this information and describes how it accounts for both the specificity and degeneracy of peptide binding. It also considers how the origin and structural features of peptides that have been isolated from MHC molecules, so-called "naturally processed" peptides, have provided insight into the pathways through which the peptides are produced. Finally, the use of new structural information and techniques for peptide characterization for the identification of peptides that comprise epitopes for individual antigen-specific T cells are considered.
Error in Figures
Authors: Rodrigo Mansur, Roger Mcintyre, Elisa Brietzke
Journal: JAMA Pediatrics (2018)

Jessica D. Forbes, PhD; Meghan B. Azad, PhD; Lorena Vehling, MSc; Hein M. Tun, PhD; Theodore B. Konya, MPH; David S. Guttman, PhD; Catherine J. Field, PhD; Diana Lefebvre, PhD; Malcolm R. Sears, MBChB; Allan B. Becker, MD; Piushkumar J. Mandhane, MD, PhD; Stuart E. Turvey, MBBS, DPhil; Theo J. Moraes, MD, PhD; Padmaja Subbarao, MD, MSc; James A. Scott, PhD; Anita L. Kozyrskyj, PhD; for the Canadian Healthy Infant Longitudinal Development (CHILD) Study Investigators
A Pictorial Atlas of Skin Diseases and Syphilitic Affections, in in photo-lithochromes from models in the museum of the Saint Louis Hospital, Paris, with explanatory wood-cuts and texts.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2911: T-182C Polymorphism in the Norepinephrine Transporter Gene (SLC6A2) and Risk of Cardiovascular Events in Patients with Dilated Cardiomyopathy: Association of the T allele with a Reduced Risk for Cardiovascular Events
Authors: TAKAYUKI NAGAI, Akiyoshi Ogimoto, Kazuhisa Nishimura, Akira Kurata, Jun Suzuki, Tomoaki Ohtsuka, Hideki Okayama, Tetsuro Miki, Jitsuo Higaki
Journal: Circulation (2007)

Backgrounds: The increase in sympathetic activity is one of the hallmarks of the chronic heart failure and has been shown to have an important impact on survival in patients with dilated cardiomyopathy (DCM). Norepinephrine transporter (NET) recaptures as much as 90% of released norepinephrine in the heart, making it a critical mediator of norepinephrine inactivation and presynaptic catecholamine homeostasis. Recently, the polymorphism of NET T-182C was reported to be associated with the improvement of left ventricular systolic function by beta-blockers in patients with DCM. However, the association between the incidence of cardiovascular events and the NET polymorphism in patients DCM has not been understood. The purpose of this study was to evaluate the effect of this polymorphism on the incidence of cardiovascular events in patients with DCM. Methods: Eighty-three genetically unrelated patients with nonfamilial DCM (64 males, mean age at initial clinical evaluation 59 ± 14 years) were enrolled in this study. An adverse cardiovascular event was defined as cardiac death or hospitalization for cardiac reasons. The time to the first adverse cardiovascular event was analyzed by the Kaplan-Meier method. The TaqMan polymerase chain reaction method was used for the determination of genotypes of the NET T-182C gene (SLC6A2) (rs#2242446). Results: The distribution of the NET T-182C genotypes (T/T, T/C, and C/C) was 43%, 45%, and 12%, respectively. The NET T-182C T allele frequency was 0.63. During a mean follow-up period of 45 months, 20 cardiovascular events had occurred. Eight patients died from cardiac cause (1 from pump failure and 7 from sudden cardiac death) and there were 12 hospitalizations for new onset or worsening of heart failure symptoms. The cardiovascular event rate of the patients carrying the T allele (T/T and T/C genotype, n = 73) was significantly lower than that of the patients not carrying the T allele (C/C genotype, n = 10) (p = 0.03). Conclusion: Our data suggested that the T allele of the NET T-182C gene may be a protective factor against cardiovascular events in patients with DCM.
Physician assignment policies of the US Army
Authors: B. H. Berrey
Journal: JAMA (1966)

"Will I be used in my specialty? I don't care where I go, just let me work in my specialty." Such questions and statements are repeated daily in interviews with physicians about to enter active duty under the aegis of Selective Service (and to a lesser extent from Berry Plan participants). The consistent regularity of these comments indicates that a paucity of information exists concerning physician classification and assignment procedures of the Surgeon General, Department of the Army. The purpose of this communication is to identify the procedures used by the Medical Corps Branch, Office of the Surgeon General, to assure the most effective utilization of the newly commissioned physician. It is not the purpose to discuss selective service methods, commissioning procedures or other administrative techniques used in bringing the qualified physician to active duty. Our attention, therefore, is directed solely to the initial assignment procedure which cannot begin until the individual's preference questionnaire is received in the
Blastomycosis Acquired Occupationally During Prairie Dog Relocation-- Colorado, 1998
Journal: JAMA (1999)

On August 31, 1998, two suspected cases of fungal pneumonia were reported to the Boulder County (Colorado) Health Department (BCHD). Both patients were immunocompetent, otherwise healthy adults working for the City of Boulder Open Space (CBOS) program on a prairie dog relocation project. This report summarizes the epidemiologic investigation by BCHD, the Colorado Department of Public Health and Environment, and CDC; the findings indicate that these two persons acquired blastomycosis in Colorado, which is outside the area where the disease is endemic.